Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Embryo Movement Stimulates Joint Formation
A new study uncovers a molecular mechanism that explains why joints fail to develop in embryos with paralyzed limbs. The research, published by Cell Press in the May issue of the journal Developmental Cell, answers a longstanding question about the influence of muscle activity on developing joints and underscores the critical contribution of movement to regulation of a signaling pathway that is important during development and beyond.
generic viagra online
NIST Researchers 'All Aglow' Over New Test Of Toxin Strength
A new National Institute of Standards and Technology (NIST) assay using a "glow or no glow" technique may soon help the U.S. Department of Homeland Security (DHS) defend the nation against a spectrum of biological weapons that could be used in a terrorist attack. One very dangerous toxin on the list is ricin, a protein derived from castor beans that is lethal in doses as small as 500 micrograms - about the size of a grain of salt.
News of the day
UCB's Cimzia(R) Approved In The U.S. For Adult Patients Suffering From Moderate To Severe Rheumatoid Arthritis
Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the U.S. Food and Drug Administration (FDA) has approved Cimzia®, for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). Cimzia® (certolizumab pegol), is a PEGylated anti-TNFa (Tumor Necrosis Factor alpha). The product is currently being developed by UCB. Cimzia is one of several products which utilize Enzon"s PEGylation technology, including PEG-INTRON®, Macugen®, and Pegasys®.
Oncology

Cegedim Dendrite Launches Innovative COUNTERxFEIT DETECT Program

Cegedim Dendrite announced the launch of COUNTERxFEIT DETECT, a new offering that will assist pharmaceutical companies in identifying counterfeit product and determining where it entered their United States supply chains. Cegedim Dendrite is the leading provider of compliance technology solutions and services in the pharmaceutical industry. Counterfeit medicines represent a significant public health and safety issue for consumers. It also poses serious business and financial risks for manufacturers, including possible liability issues, lost revenue, erosion of brand confidence and negative public perception. COUNTERxFEIT DETECT is designed for pharmaceutical companies that need to identify and determine the of counterfeit, contaminated or adulterated product. Cegedim Dendrite facilitates this by coordinating the purchase of non-controlled, finished drug products from contract manufacturers or distributors, using an independent pharmaceutical buyer. The product is shipped to a testing facility or the pharmaceutical company"s analytical lab, where the product is analyzed. "Drug counterfeiting is a concern in the pharmaceutical industry with estimates indicating that upward of 8% of pharmaceutical medicines worldwide may be counterfeit," explained Bill Buzzeo, Cegedim Dendrite Vice President and General Manager, Compliance Solutions and OneKey. "As part of their anti-counterfeiting programs, pharmaceutical companies should acquire finished drug products within the supply chain for analysis and testing to ensure their quality. We seamlessly facilitate that process, and as far as we know, we"re the only company that offers this type of program." Cegedim Dendrite"s independent purchasing of finished drug product takes the burden off the pharmaceutical company"s internal res. COUNTERxFEIT DETECT is fully secure and includes appropriate audit trail documentation that provides insight into the full acquisition chain associated with the independent pharmacy"s purchase. "If an independent party is making the purchase," said Buzzeo, "the pharmaceutical company can better show that they had a random sample for testing and that the process was not tainted by anyone internally with false motive." Cegedim Dendrite has been providing comprehensive compliance solutions to a broad range of pharmacy clients for 20 years. The company employs former state and federal regulators whose firsthand experience with compliance, fraud and abuse issues enable them to develop real-world prevention programs. About Cegedim Dendrite Cegedim Dendrite is the life sciences industry"s leading provider of Customer Relationship Management (CRM) solutions. Pharmaceutical by design, the company"s innovative business solutions and global reach incorporate a thorough understanding of local, regional and worldwide trends. Cegedim Dendrite enables more than 200,000 users in many of the world"s top companies to stay ahead of market challenges. Cegedim Dendrite also provides sales, marketing and regulatory compliance solutions in more than 80 countries. Cegedim Dendrite is part of the France-based Cegedim S.A. Group. To learn more, please visit http://www.cegedimdendrite.com. Cegedim


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009